Product Reports Resources Pricing Login Book a demo

Tessera Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2018

A new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source

Valuation $1–2.5B
Revenue $100–500M
Headcount 100–500
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Tessera Therapeutics and the history behind them.
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Investors

16 investors on Tessera Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 16 investors entered at this stage
Regeneron Pharmaceuticals
Alaska Permanent Fund
March Capital Partners
Artis Ventures
Abu Dhabi Investment Authority
Altitude Life Science Ventures
Cormorant Asset Management
Longevity Vision Fund
SoftBank
University of California
Berkeley
T. Rowe Price
SALT Fund
Qatar Investment Authority
Hanwha Impact
Flagship Pioneering

Tessera Therapeutics mafia

Startups founded by Tessera Therapeutics alumni

Former Tessera Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

Liberate BioEst. 2022
Michael J MitchellUnited States
Signal score89
Generate BiomedicinesEst. 2020
Molly GibsonUnited States
Signal score74
Quotient TherapeuticsEst. 2022
Jacob Rubens.United Kingdom
Signal score73
Montai HealthEst. 2022
Noubar AfeyanUnited States
Signal score68
Via ScientificEst. 2022
MMMelissa J. MooreUnited States
Signal score54

Book a demo to explore the full alumni network →

Global footprint

Where Tessera Therapeutics has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States98.9%
🇮🇹 Italy1.1%
2 countries shown
Web traffic by country
7.9K monthly visits
across markets
🇺🇸 United States81%
🇯🇵 Japan8.9%
🇮🇳 India6.3%
🇵🇭 Philippines3.8%
🇬🇧 United Kingdom1.3%
Top 5 markets shown

Talent graph

The shape of Tessera Therapeutics's talent

Dealroom maps Tessera Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

9 standout operatorsDealroom-flagged across the org
5 AI specialistsincl. 5 core researchers
197 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Tessera Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$127k patent portfolio · 9 active families

Estimated portfolio value
$127k
<0.01% of valuation · 1198.1× smaller than top peer Cellectis ($152M)
9 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Tessera Therapeutics

An AI-synthesized read of the highest-engagement posts about Tessera Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tessera Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles